{"gene":"FBXO44","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2020,"finding":"FBXO44 binds H3K9me3-modified nucleosomes at the replication fork and recruits SUV39H1, CRL4, and Mi-2/NuRD complexes to transcriptionally silence repetitive elements (REs) post-DNA replication in cancer cells. Inhibition of FBXO44/SUV39H1 reactivates REs, causing DNA replication stress and activation of MAVS/STING antiviral and interferon signaling pathways.","method":"RNAi screen, Co-IP, chromatin fractionation, loss-of-function with defined molecular and cellular phenotypic readouts","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — high-content RNAi screen with multiple orthogonal mechanistic validations, replicated across multiple cancer cell lines","pmids":["33357448"],"is_preprint":false},{"year":2012,"finding":"The SCF(FBXO44) complex (Skp1-Cul1-FBXO44) ubiquitinates full-length BRCA1 in vitro, mediating its proteasomal degradation. The N-terminus of BRCA1 mediates interaction with FBXO44.","method":"Mass spectrometry identification of Skp1, siRNA screen of F-box proteins, in vitro ubiquitination assay, Co-IP, overexpression/knockdown with protein level readout","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro ubiquitination assay combined with Co-IP and siRNA validation with defined substrate","pmids":["23086937"],"is_preprint":false},{"year":2015,"finding":"FBXO44 mediates proteasomal degradation of RGS2 through a novel E3 ligase complex containing cullin 4B (CUL4B) and DDB1, distinct from the canonical SCF complex (CUL1/Skp1). The CUL1/Skp1-containing FBXO44 complex does not bind RGS2 and is not involved in RGS2 degradation.","method":"Genomic siRNA screening, Co-IP, proteasomal inhibition assays, knockdown experiments","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genome-wide siRNA screen with reciprocal Co-IP and mechanistic dissection of two distinct FBXO44 complexes","pmids":["25970626"],"is_preprint":false},{"year":2020,"finding":"RGS2 associates with FBXO44 through a stretch of residues in its N-terminus. Shorter N-terminal translation initiation variants of RGS2 display reduced ubiquitination and proteasomal degradation due to lost association with FBXO44. Phosphorylation of Ser3 of RGS2 protects it from FBXO44-mediated proteasomal degradation.","method":"Co-IP, ubiquitination assays, proteasomal inhibition, site-directed mutagenesis of RGS2 N-terminal residues","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis with Co-IP and ubiquitination assays defining specific degron residues and phosphorylation-based protection","pmids":["33008920"],"is_preprint":false},{"year":2008,"finding":"FBXO44 (FBX044) belongs to the FBA family of F-box proteins but, unlike FBXO2, FBXO6, FBXO17, and FBXO27, fails to bind any glycans on glycan arrays. FBXO44 co-precipitates components of the canonical SCF complex (Skp1, Cullin1, and Rbx1). Two aromatic amino acids in the conserved G domain create a hydrophobic pocket necessary for high-affinity glycan binding in other FBA members.","method":"Glycan arrays, site-directed mutagenesis, Co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — glycan array screening with mutagenesis and Co-IP across multiple family members","pmids":["18203720"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of the Skp1-FBG3 (FBXO44) complex determined at 2.6 Å resolution. The substrate-binding domain of FBG3 is a 10-stranded antiparallel β-sandwich with three helices. Despite high sequence similarity to Fbs1, distinct hydrogen bond networks in four loops (β2-β3, β5-β6, β7-β8, β9-β10) of FBG3 prevent formation of the carbohydrate-binding pocket present in Fbs1, explaining its lack of glycan binding.","method":"X-ray crystallography, structure-based mutational analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — crystal structure at 2.6 Å with structure-based mutagenesis confirming mechanism of lost glycan binding","pmids":["26460611"],"is_preprint":false},{"year":2011,"finding":"Skp1 co-expression with FBXO44 (Fbg5) facilitates its proper folding and ability to bind glycoproteins, and increases cellular concentrations by preventing aggregate formation. FBXO44/Fbg5 forms an SCF complex but does not bind N-glycoproteins when expressed alone.","method":"Co-expression, ConA-binding assay, co-immunoprecipitation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — single lab, multiple complementary methods showing Skp1-dependent folding and substrate binding","pmids":["21640084"],"is_preprint":false},{"year":2023,"finding":"FBXO44 interacts with PXR (pregnane X receptor) through its F-box associated domain (binding the PXR ligand binding domain), leading to PXR ubiquitination and proteasomal degradation. FBXO44 knockdown increases PXR abundance; overexpression decreases it, with downstream consequences for CYP3A4 levels.","method":"RNAi library screen, Co-IP, ubiquitination assay, domain-mapping by mutagenesis/truncation, overexpression/knockdown with protein level readouts","journal":"Acta pharmaceutica Sinica. B","confidence":"High","confidence_rationale":"Tier 1-2 — RNAi screen hit validated with Co-IP, ubiquitination assay, domain mapping, and bidirectional modulation of substrate","pmids":["37969738"],"is_preprint":false},{"year":2025,"finding":"FBXO44 targets FOXP1 for proteasomal degradation via K48-linked ubiquitination at K377. Aurora kinase A (AURKA) phosphorylates FOXP1 at Ser440, enhancing FBXO44 binding. FOXP1 degradation relieves its repression of Cyclin E2, promoting colorectal cancer cell proliferation.","method":"Co-IP, ubiquitination assay with K48-linkage specificity, phosphomimetic/phospho-null mutagenesis, AURKA kinase assay, knockdown/overexpression with proliferation and tumor growth readouts","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro ubiquitination with linkage specificity, kinase-phosphorylation-dependent substrate recognition, and in vivo xenograft validation","pmids":["41051444"],"is_preprint":false},{"year":2025,"finding":"Systematic peptide array scanning of the RGS2 N-terminal degron identified specific residues required for FBXO44 binding. AlphaFold modeling and molecular dynamics simulations predicted structural features of the RGS2-FBXO44 interaction, confirmed by Co-IP and proteasomal inhibition in cells using full-length RGS2 with substituted residues.","method":"Peptide array with systematic residue substitution, AlphaFold/molecular dynamics modeling, Co-IP, proteasomal inhibition assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — peptide array and computational modeling orthogonally validated in cells, single lab","pmids":["40992661"],"is_preprint":false},{"year":2025,"finding":"A NanoBiT protein-protein interaction assay detected the direct RGS2-FBXO44 interaction. A small-molecule inhibitor (compound 10) inhibits the RGS2-FBXO44 interaction with a potency of 19.6 μM through direct binding to RGS2, increasing RGS2 protein levels in a FBXO44-dependent manner (siRNA FBXO44 knockdown attenuated this effect).","method":"NanoBiT assay, compound library screening, siRNA knockdown, protein level measurement","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2-3 — PPI assay with pharmacological probe and genetic validation, single lab","pmids":["40199141"],"is_preprint":false},{"year":2002,"finding":"FBXO44 (FBG5) was identified as a novel F-box protein with a conserved ~180 amino acid C-terminal domain shared among the FBA subfamily (FBXO2, FBXO6, FBXO17, FBXO27, FBXO44). Its gene consists of six exons and five introns, mapped to chromosome 19q13, and is expressed in a limited number of tissues.","method":"cDNA cloning, genomic organization analysis, tissue expression profiling","journal":"Gene","confidence":"Low","confidence_rationale":"Tier 4 — discovery paper, gene identification without direct functional mechanistic assay for FBXO44 specifically","pmids":["12383498"],"is_preprint":false}],"current_model":"FBXO44 is an F-box protein that functions as the substrate recognition component of at least two distinct E3 ubiquitin ligase complexes — a canonical SCF complex (Skp1/CUL1/RBX1) and a non-canonical CUL4B/DDB1 complex — to ubiquitinate and proteasomally degrade multiple substrates including BRCA1, RGS2, PXR, and FOXP1 (the latter requiring prior AURKA-mediated phosphorylation); additionally, FBXO44 binds H3K9me3-modified nucleosomes at replication forks and recruits SUV39H1, CRL4, and Mi-2/NuRD to epigenetically silence repetitive elements post-DNA replication, a function that is cancer cell-specific and whose inhibition triggers viral mimicry and enhanced immunotherapy response."},"narrative":{"teleology":[{"year":2002,"claim":"Identification of FBXO44 as a novel FBA-subfamily F-box protein established it as a potential SCF E3 ligase component with a conserved ~180 aa C-terminal domain, setting the stage for functional characterization.","evidence":"cDNA cloning, genomic mapping, and tissue expression profiling","pmids":["12383498"],"confidence":"Low","gaps":["No functional or substrate data; gene identification only","Tissue expression limited to Northern analysis without protein-level validation"]},{"year":2008,"claim":"Demonstrating that FBXO44 assembles into a canonical SCF complex yet uniquely fails to bind glycans among FBA family members raised the question of what its true substrates are.","evidence":"Glycan array screening across FBA family, Co-IP of Skp1/CUL1/RBX1, site-directed mutagenesis of glycan-binding residues","pmids":["18203720"],"confidence":"High","gaps":["No endogenous substrate identified","Basis for loss of glycan binding was inferred but not structurally resolved"]},{"year":2011,"claim":"Showing that Skp1 co-expression is required for FBXO44 folding and prevents aggregation revealed a chaperone-like dependency that explained why isolated FBXO44 appeared non-functional in earlier assays.","evidence":"Co-expression with Skp1, ConA-binding assay, Co-IP","pmids":["21640084"],"confidence":"Medium","gaps":["Single lab study","Whether Skp1 dependency extends to all FBXO44 complexes (e.g., CUL4B-based) was not tested"]},{"year":2012,"claim":"Identification of BRCA1 as the first bona fide SCF(FBXO44) substrate demonstrated that this atypical FBA member functions as a protein-targeting E3 ligase rather than a glycoprotein-targeting one.","evidence":"Mass spectrometry, siRNA screen of F-box proteins, in vitro ubiquitination assay, Co-IP with domain mapping","pmids":["23086937"],"confidence":"High","gaps":["Physiological contexts triggering BRCA1 degradation not defined","Whether FBXO44-mediated BRCA1 turnover affects DNA damage responses not tested"]},{"year":2015,"claim":"Discovery that FBXO44 degrades RGS2 through a non-canonical CUL4B/DDB1 complex—not the SCF complex—revealed that FBXO44 operates in at least two distinct E3 ligase architectures with different substrate specificities.","evidence":"Genome-wide siRNA screen, reciprocal Co-IP distinguishing CUL1- and CUL4B-containing complexes, proteasomal inhibition","pmids":["25970626"],"confidence":"High","gaps":["How FBXO44 is partitioned between SCF and CUL4B complexes is unknown","Whether additional cullins are involved was not explored"]},{"year":2015,"claim":"The 2.6 Å crystal structure of Skp1–FBXO44 resolved the structural basis for loss of glycan binding: altered hydrogen-bond networks in four loops collapse the carbohydrate pocket, confirming FBXO44 engages non-glycan substrates.","evidence":"X-ray crystallography at 2.6 Å, structure-based mutagenesis","pmids":["26460611"],"confidence":"High","gaps":["No co-crystal with any protein substrate obtained","Structure represents only the SCF-associated form, not the CUL4B complex"]},{"year":2020,"claim":"Mapping the RGS2 N-terminal degron and showing that Ser3 phosphorylation blocks FBXO44 binding established a phosphorylation-dependent switch that protects RGS2 from degradation, paralleling classical phosphodegron logic in reverse.","evidence":"Site-directed mutagenesis, Co-IP, ubiquitination assays with RGS2 variants","pmids":["33008920"],"confidence":"High","gaps":["Kinase responsible for Ser3 phosphorylation not identified","In vivo relevance of phospho-protection not demonstrated"]},{"year":2020,"claim":"Discovery that FBXO44 binds H3K9me3-marked nucleosomes at replication forks to recruit SUV39H1/CRL4/NuRD for post-replicative silencing of repetitive elements revealed a chromatin-regulatory function entirely distinct from its proteolytic roles, and linked its loss to viral mimicry and immunotherapy sensitization in cancer.","evidence":"RNAi screen, Co-IP, chromatin fractionation, loss-of-function across multiple cancer cell lines with MAVS/STING pathway readouts","pmids":["33357448"],"confidence":"High","gaps":["Whether the chromatin function uses the CUL4B or SCF complex or neither is unclear","Mechanism of H3K9me3 recognition by FBXO44 not structurally defined","Whether this silencing role operates in normal (non-cancer) cells is unknown"]},{"year":2023,"claim":"Identification of the nuclear receptor PXR as an FBXO44 substrate, with binding mediated through the F-box-associated domain to the PXR ligand-binding domain, extended the substrate repertoire to xenobiotic-sensing pathways.","evidence":"RNAi library screen, Co-IP, ubiquitination assay, domain-mapping truncations, bidirectional modulation of PXR levels","pmids":["37969738"],"confidence":"High","gaps":["Which cullin complex mediates PXR ubiquitination not determined","Whether ligand occupancy of PXR modulates FBXO44-mediated turnover not tested"]},{"year":2025,"claim":"Demonstration that AURKA phosphorylates FOXP1 at Ser440 to create a phosphodegron recognized by FBXO44, leading to K48-linked ubiquitination at K377 and derepression of Cyclin E2, established a kinase–E3 ligase axis driving colorectal cancer proliferation.","evidence":"Co-IP, K48-linkage-specific ubiquitination, phosphomimetic mutagenesis, AURKA kinase assay, in vivo xenograft","pmids":["41051444"],"confidence":"High","gaps":["Whether other kinases can substitute for AURKA not explored","Generalizability beyond colorectal cancer models not tested"]},{"year":2025,"claim":"Fine-mapping of the RGS2–FBXO44 interface by peptide arrays and AlphaFold modeling, together with identification of a small-molecule inhibitor of this interaction, provided proof-of-concept that FBXO44 substrate engagement is pharmacologically tractable.","evidence":"Systematic peptide array, AlphaFold/MD simulations, NanoBiT PPI assay, compound screening with siRNA validation","pmids":["40992661","40199141"],"confidence":"Medium","gaps":["Inhibitor potency (19.6 µM) is modest; selectivity and in vivo efficacy untested","Structural model is computationally predicted and awaits experimental co-structure"]},{"year":null,"claim":"Key unresolved questions include how FBXO44 is partitioned between SCF and CUL4B complexes, the structural basis of H3K9me3 nucleosome recognition, whether the chromatin-silencing function is ubiquitin-dependent, and whether additional physiological substrates exist.","evidence":"","pmids":[],"confidence":"High","gaps":["No co-structure of FBXO44 with any protein substrate","Mechanism linking FBXO44 to H3K9me3 not structurally resolved","Regulation of FBXO44 expression and turnover largely unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,3,7,8]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,7]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,2,3,7,8]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[0]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[8]}],"complexes":["SCF(FBXO44) (Skp1/CUL1/RBX1/FBXO44)","CUL4B/DDB1/FBXO44"],"partners":["SKP1","CUL1","CUL4B","DDB1","SUV39H1","BRCA1","RGS2","FOXP1"],"other_free_text":[]},"mechanistic_narrative":"FBXO44 is an F-box protein that functions as the substrate-recognition subunit of both canonical SCF (Skp1/CUL1/RBX1) and non-canonical CUL4B/DDB1 E3 ubiquitin ligase complexes to target multiple substrates—including BRCA1, RGS2, PXR, and FOXP1—for K48-linked ubiquitination and proteasomal degradation [PMID:23086937, PMID:25970626, PMID:37969738, PMID:41051444]. Substrate selection is regulated by degron-specific mechanisms: FOXP1 degradation requires prior AURKA-mediated phosphorylation at Ser440, whereas RGS2 degradation is inhibited by phosphorylation of its N-terminal Ser3 [PMID:41051444, PMID:33008920]. Structurally, FBXO44 belongs to the FBA subfamily but has a remodeled substrate-binding β-sandwich that lacks the carbohydrate-binding pocket of glycan-recognizing paralogs, instead engaging protein substrates through its F-box-associated domain [PMID:26460611, PMID:18203720]. Independent of its role in targeted proteolysis, FBXO44 binds H3K9me3-marked nucleosomes at replication forks and recruits SUV39H1, CRL4, and Mi-2/NuRD to maintain epigenetic silencing of repetitive elements in cancer cells; loss of this function reactivates repetitive elements, triggers MAVS/STING-dependent viral mimicry, and sensitizes tumors to immunotherapy [PMID:33357448]."},"prefetch_data":{"uniprot":{"accession":"Q9H4M3","full_name":"F-box only protein 44","aliases":["F-box protein FBX30","F-box/G-domain protein 3"],"length_aa":255,"mass_kda":29.7,"function":"Substrate-recognition component of two distinct E3 ligase complexes, the SKP1-CUL1-FBXO44 complex and the CUL4B-DDB1-FBXO44 complex (PubMed:18203720, PubMed:25970626). The complex SCF(FBXO44) complex ubiquitinates and mediates BRCA1 degradation (PubMed:23086937). In association with cullin 4B/CUL4B and DDB1, mediates the ubiquitination of RGS2 leading to its degradation (PubMed:25970626). Additionally, regulates the pregnane X receptor/NR1I2 protein level by ubiquitination and degradation (PubMed:37969738)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H4M3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FBXO44","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FBXO44","total_profiled":1310},"omim":[{"mim_id":"609111","title":"F-BOX ONLY PROTEIN 44; FBXO44","url":"https://www.omim.org/entry/609111"},{"mim_id":"607112","title":"F-BOX ONLY PROTEIN 2; FBXO2","url":"https://www.omim.org/entry/607112"},{"mim_id":"605647","title":"F-BOX ONLY PROTEIN 6; FBXO6","url":"https://www.omim.org/entry/605647"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":260.4}],"url":"https://www.proteinatlas.org/search/FBXO44"},"hgnc":{"alias_symbol":["FBX30","FBG3","MGC14140","Fbxo6a","Fbx44"],"prev_symbol":[]},"alphafold":{"accession":"Q9H4M3","domains":[{"cath_id":"1.20.1280.50","chopping":"5-70","consensus_level":"high","plddt":93.0076,"start":5,"end":70},{"cath_id":"2.60.120.260","chopping":"78-163_220-231_242-255","consensus_level":"medium","plddt":94.0034,"start":78,"end":255}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4M3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4M3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4M3-F1-predicted_aligned_error_v6.png","plddt_mean":92.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FBXO44","jax_strain_url":"https://www.jax.org/strain/search?query=FBXO44"},"sequence":{"accession":"Q9H4M3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H4M3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H4M3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4M3"}},"corpus_meta":[{"pmid":"33357448","id":"PMC_33357448","title":"FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33357448","citation_count":87,"is_preprint":false},{"pmid":"18203720","id":"PMC_18203720","title":"Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18203720","citation_count":65,"is_preprint":false},{"pmid":"23086937","id":"PMC_23086937","title":"The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23086937","citation_count":54,"is_preprint":false},{"pmid":"36774361","id":"PMC_36774361","title":"Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36774361","citation_count":34,"is_preprint":false},{"pmid":"12383498","id":"PMC_12383498","title":"A new subfamily of structurally related human F-box proteins.","date":"2002","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/12383498","citation_count":31,"is_preprint":false},{"pmid":"25970626","id":"PMC_25970626","title":"FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25970626","citation_count":27,"is_preprint":false},{"pmid":"34777457","id":"PMC_34777457","title":"Evaluation of Seasonal Heat Stress on Transcriptomic Profiles and Global DNA Methylation of Bovine Oocytes.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34777457","citation_count":26,"is_preprint":false},{"pmid":"21640084","id":"PMC_21640084","title":"Skp1 stabilizes the conformation of F-box proteins.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21640084","citation_count":26,"is_preprint":false},{"pmid":"37595030","id":"PMC_37595030","title":"Steerable Microneedles Enabling Deep Delivery of Photosensitizers and CRISPR/Cas9 Systems for Effective Combination Cancer Therapy.","date":"2023","source":"Nano letters","url":"https://pubmed.ncbi.nlm.nih.gov/37595030","citation_count":22,"is_preprint":false},{"pmid":"33745150","id":"PMC_33745150","title":"Genome-wide association study of stage III/IV grade C periodontitis (former aggressive periodontitis) in a Spanish population.","date":"2021","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/33745150","citation_count":18,"is_preprint":false},{"pmid":"26460611","id":"PMC_26460611","title":"The Structural Differences between a Glycoprotein Specific F-Box Protein Fbs1 and Its Homologous Protein FBG3.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26460611","citation_count":15,"is_preprint":false},{"pmid":"33008920","id":"PMC_33008920","title":"N-Terminal Targeting of Regulator of G Protein Signaling Protein 2 for F-Box Only Protein 44-Mediated Proteasomal Degradation.","date":"2020","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33008920","citation_count":12,"is_preprint":false},{"pmid":"37969738","id":"PMC_37969738","title":"The F-box-only protein 44 regulates pregnane X receptor protein level by ubiquitination and degradation.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/37969738","citation_count":10,"is_preprint":false},{"pmid":"23185754","id":"PMC_23185754","title":"[Study on gene differential expressions of substance and energy metabolism in chronic superficial gastritis patients of Pi deficiency syndrome and of pi-wei hygropyrexia syndrome].","date":"2012","source":"Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23185754","citation_count":7,"is_preprint":false},{"pmid":"40199141","id":"PMC_40199141","title":"Discovery of RGS2-FBXO44 interaction inhibitors using a cell-based NanoBit assay.","date":"2025","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40199141","citation_count":5,"is_preprint":false},{"pmid":"39733911","id":"PMC_39733911","title":"Core-shell vector-mediated co-delivery of CRISPR/Cas9 system and hydrophobic drugs against triple-negative breast cancer stem cells.","date":"2025","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/39733911","citation_count":5,"is_preprint":false},{"pmid":"27487926","id":"PMC_27487926","title":"Structural analysis of a function-associated loop mutant of the substrate-recognition domain of Fbs1 ubiquitin ligase.","date":"2016","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/27487926","citation_count":5,"is_preprint":false},{"pmid":"38338834","id":"PMC_38338834","title":"Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38338834","citation_count":5,"is_preprint":false},{"pmid":"33681705","id":"PMC_33681705","title":"Targeting FBXO44/SUV39H1 elicits tumor cell-specific DNA replication stress and viral mimicry.","date":"2021","source":"Cell stress","url":"https://pubmed.ncbi.nlm.nih.gov/33681705","citation_count":4,"is_preprint":false},{"pmid":"39577754","id":"PMC_39577754","title":"Role for the F-box proteins in heart diseases.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39577754","citation_count":4,"is_preprint":false},{"pmid":"39511641","id":"PMC_39511641","title":"EZH1/2 plays critical roles in oocyte meiosis prophase I in mice.","date":"2024","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/39511641","citation_count":3,"is_preprint":false},{"pmid":"41051444","id":"PMC_41051444","title":"FBXO44 Regulates FOXP1 Degradation Through AURKA-Dependent Phosphorylation to Promote Colorectal Cancer Progression.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41051444","citation_count":2,"is_preprint":false},{"pmid":"20057081","id":"PMC_20057081","title":"Crystallization and preliminary X-ray characterization of the Skp1-Fbg3 complex.","date":"2009","source":"Acta crystallographica. Section F, Structural biology and crystallization communications","url":"https://pubmed.ncbi.nlm.nih.gov/20057081","citation_count":2,"is_preprint":false},{"pmid":"35713327","id":"PMC_35713327","title":"Focal facial dermal dysplasias type III: Two families with Setleis syndrome in China.","date":"2022","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35713327","citation_count":2,"is_preprint":false},{"pmid":"40992661","id":"PMC_40992661","title":"Systematic analysis of the RGS2 degron reveals characteristics of substrate recognition by the F-box protein FBXO44.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40992661","citation_count":0,"is_preprint":false},{"pmid":"40341176","id":"PMC_40341176","title":"OTX2 expression contributes progression of gastric cancer in young adults.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40341176","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14392,"output_tokens":3103,"usd":0.04486},"stage2":{"model":"claude-opus-4-6","input_tokens":6494,"output_tokens":3073,"usd":0.163942},"total_usd":0.208802,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"FBXO44 binds H3K9me3-modified nucleosomes at the replication fork and recruits SUV39H1, CRL4, and Mi-2/NuRD complexes to transcriptionally silence repetitive elements (REs) post-DNA replication in cancer cells. Inhibition of FBXO44/SUV39H1 reactivates REs, causing DNA replication stress and activation of MAVS/STING antiviral and interferon signaling pathways.\",\n      \"method\": \"RNAi screen, Co-IP, chromatin fractionation, loss-of-function with defined molecular and cellular phenotypic readouts\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — high-content RNAi screen with multiple orthogonal mechanistic validations, replicated across multiple cancer cell lines\",\n      \"pmids\": [\"33357448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The SCF(FBXO44) complex (Skp1-Cul1-FBXO44) ubiquitinates full-length BRCA1 in vitro, mediating its proteasomal degradation. The N-terminus of BRCA1 mediates interaction with FBXO44.\",\n      \"method\": \"Mass spectrometry identification of Skp1, siRNA screen of F-box proteins, in vitro ubiquitination assay, Co-IP, overexpression/knockdown with protein level readout\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro ubiquitination assay combined with Co-IP and siRNA validation with defined substrate\",\n      \"pmids\": [\"23086937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FBXO44 mediates proteasomal degradation of RGS2 through a novel E3 ligase complex containing cullin 4B (CUL4B) and DDB1, distinct from the canonical SCF complex (CUL1/Skp1). The CUL1/Skp1-containing FBXO44 complex does not bind RGS2 and is not involved in RGS2 degradation.\",\n      \"method\": \"Genomic siRNA screening, Co-IP, proteasomal inhibition assays, knockdown experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide siRNA screen with reciprocal Co-IP and mechanistic dissection of two distinct FBXO44 complexes\",\n      \"pmids\": [\"25970626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RGS2 associates with FBXO44 through a stretch of residues in its N-terminus. Shorter N-terminal translation initiation variants of RGS2 display reduced ubiquitination and proteasomal degradation due to lost association with FBXO44. Phosphorylation of Ser3 of RGS2 protects it from FBXO44-mediated proteasomal degradation.\",\n      \"method\": \"Co-IP, ubiquitination assays, proteasomal inhibition, site-directed mutagenesis of RGS2 N-terminal residues\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis with Co-IP and ubiquitination assays defining specific degron residues and phosphorylation-based protection\",\n      \"pmids\": [\"33008920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FBXO44 (FBX044) belongs to the FBA family of F-box proteins but, unlike FBXO2, FBXO6, FBXO17, and FBXO27, fails to bind any glycans on glycan arrays. FBXO44 co-precipitates components of the canonical SCF complex (Skp1, Cullin1, and Rbx1). Two aromatic amino acids in the conserved G domain create a hydrophobic pocket necessary for high-affinity glycan binding in other FBA members.\",\n      \"method\": \"Glycan arrays, site-directed mutagenesis, Co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — glycan array screening with mutagenesis and Co-IP across multiple family members\",\n      \"pmids\": [\"18203720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of the Skp1-FBG3 (FBXO44) complex determined at 2.6 Å resolution. The substrate-binding domain of FBG3 is a 10-stranded antiparallel β-sandwich with three helices. Despite high sequence similarity to Fbs1, distinct hydrogen bond networks in four loops (β2-β3, β5-β6, β7-β8, β9-β10) of FBG3 prevent formation of the carbohydrate-binding pocket present in Fbs1, explaining its lack of glycan binding.\",\n      \"method\": \"X-ray crystallography, structure-based mutational analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure at 2.6 Å with structure-based mutagenesis confirming mechanism of lost glycan binding\",\n      \"pmids\": [\"26460611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Skp1 co-expression with FBXO44 (Fbg5) facilitates its proper folding and ability to bind glycoproteins, and increases cellular concentrations by preventing aggregate formation. FBXO44/Fbg5 forms an SCF complex but does not bind N-glycoproteins when expressed alone.\",\n      \"method\": \"Co-expression, ConA-binding assay, co-immunoprecipitation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — single lab, multiple complementary methods showing Skp1-dependent folding and substrate binding\",\n      \"pmids\": [\"21640084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FBXO44 interacts with PXR (pregnane X receptor) through its F-box associated domain (binding the PXR ligand binding domain), leading to PXR ubiquitination and proteasomal degradation. FBXO44 knockdown increases PXR abundance; overexpression decreases it, with downstream consequences for CYP3A4 levels.\",\n      \"method\": \"RNAi library screen, Co-IP, ubiquitination assay, domain-mapping by mutagenesis/truncation, overexpression/knockdown with protein level readouts\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — RNAi screen hit validated with Co-IP, ubiquitination assay, domain mapping, and bidirectional modulation of substrate\",\n      \"pmids\": [\"37969738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FBXO44 targets FOXP1 for proteasomal degradation via K48-linked ubiquitination at K377. Aurora kinase A (AURKA) phosphorylates FOXP1 at Ser440, enhancing FBXO44 binding. FOXP1 degradation relieves its repression of Cyclin E2, promoting colorectal cancer cell proliferation.\",\n      \"method\": \"Co-IP, ubiquitination assay with K48-linkage specificity, phosphomimetic/phospho-null mutagenesis, AURKA kinase assay, knockdown/overexpression with proliferation and tumor growth readouts\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro ubiquitination with linkage specificity, kinase-phosphorylation-dependent substrate recognition, and in vivo xenograft validation\",\n      \"pmids\": [\"41051444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Systematic peptide array scanning of the RGS2 N-terminal degron identified specific residues required for FBXO44 binding. AlphaFold modeling and molecular dynamics simulations predicted structural features of the RGS2-FBXO44 interaction, confirmed by Co-IP and proteasomal inhibition in cells using full-length RGS2 with substituted residues.\",\n      \"method\": \"Peptide array with systematic residue substitution, AlphaFold/molecular dynamics modeling, Co-IP, proteasomal inhibition assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — peptide array and computational modeling orthogonally validated in cells, single lab\",\n      \"pmids\": [\"40992661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A NanoBiT protein-protein interaction assay detected the direct RGS2-FBXO44 interaction. A small-molecule inhibitor (compound 10) inhibits the RGS2-FBXO44 interaction with a potency of 19.6 μM through direct binding to RGS2, increasing RGS2 protein levels in a FBXO44-dependent manner (siRNA FBXO44 knockdown attenuated this effect).\",\n      \"method\": \"NanoBiT assay, compound library screening, siRNA knockdown, protein level measurement\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — PPI assay with pharmacological probe and genetic validation, single lab\",\n      \"pmids\": [\"40199141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FBXO44 (FBG5) was identified as a novel F-box protein with a conserved ~180 amino acid C-terminal domain shared among the FBA subfamily (FBXO2, FBXO6, FBXO17, FBXO27, FBXO44). Its gene consists of six exons and five introns, mapped to chromosome 19q13, and is expressed in a limited number of tissues.\",\n      \"method\": \"cDNA cloning, genomic organization analysis, tissue expression profiling\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — discovery paper, gene identification without direct functional mechanistic assay for FBXO44 specifically\",\n      \"pmids\": [\"12383498\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FBXO44 is an F-box protein that functions as the substrate recognition component of at least two distinct E3 ubiquitin ligase complexes — a canonical SCF complex (Skp1/CUL1/RBX1) and a non-canonical CUL4B/DDB1 complex — to ubiquitinate and proteasomally degrade multiple substrates including BRCA1, RGS2, PXR, and FOXP1 (the latter requiring prior AURKA-mediated phosphorylation); additionally, FBXO44 binds H3K9me3-modified nucleosomes at replication forks and recruits SUV39H1, CRL4, and Mi-2/NuRD to epigenetically silence repetitive elements post-DNA replication, a function that is cancer cell-specific and whose inhibition triggers viral mimicry and enhanced immunotherapy response.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FBXO44 is an F-box protein that functions as the substrate-recognition subunit of both canonical SCF (Skp1/CUL1/RBX1) and non-canonical CUL4B/DDB1 E3 ubiquitin ligase complexes to target multiple substrates—including BRCA1, RGS2, PXR, and FOXP1—for K48-linked ubiquitination and proteasomal degradation [PMID:23086937, PMID:25970626, PMID:37969738, PMID:41051444]. Substrate selection is regulated by degron-specific mechanisms: FOXP1 degradation requires prior AURKA-mediated phosphorylation at Ser440, whereas RGS2 degradation is inhibited by phosphorylation of its N-terminal Ser3 [PMID:41051444, PMID:33008920]. Structurally, FBXO44 belongs to the FBA subfamily but has a remodeled substrate-binding β-sandwich that lacks the carbohydrate-binding pocket of glycan-recognizing paralogs, instead engaging protein substrates through its F-box-associated domain [PMID:26460611, PMID:18203720]. Independent of its role in targeted proteolysis, FBXO44 binds H3K9me3-marked nucleosomes at replication forks and recruits SUV39H1, CRL4, and Mi-2/NuRD to maintain epigenetic silencing of repetitive elements in cancer cells; loss of this function reactivates repetitive elements, triggers MAVS/STING-dependent viral mimicry, and sensitizes tumors to immunotherapy [PMID:33357448].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of FBXO44 as a novel FBA-subfamily F-box protein established it as a potential SCF E3 ligase component with a conserved ~180 aa C-terminal domain, setting the stage for functional characterization.\",\n      \"evidence\": \"cDNA cloning, genomic mapping, and tissue expression profiling\",\n      \"pmids\": [\"12383498\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No functional or substrate data; gene identification only\", \"Tissue expression limited to Northern analysis without protein-level validation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that FBXO44 assembles into a canonical SCF complex yet uniquely fails to bind glycans among FBA family members raised the question of what its true substrates are.\",\n      \"evidence\": \"Glycan array screening across FBA family, Co-IP of Skp1/CUL1/RBX1, site-directed mutagenesis of glycan-binding residues\",\n      \"pmids\": [\"18203720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous substrate identified\", \"Basis for loss of glycan binding was inferred but not structurally resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing that Skp1 co-expression is required for FBXO44 folding and prevents aggregation revealed a chaperone-like dependency that explained why isolated FBXO44 appeared non-functional in earlier assays.\",\n      \"evidence\": \"Co-expression with Skp1, ConA-binding assay, Co-IP\",\n      \"pmids\": [\"21640084\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab study\", \"Whether Skp1 dependency extends to all FBXO44 complexes (e.g., CUL4B-based) was not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of BRCA1 as the first bona fide SCF(FBXO44) substrate demonstrated that this atypical FBA member functions as a protein-targeting E3 ligase rather than a glycoprotein-targeting one.\",\n      \"evidence\": \"Mass spectrometry, siRNA screen of F-box proteins, in vitro ubiquitination assay, Co-IP with domain mapping\",\n      \"pmids\": [\"23086937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts triggering BRCA1 degradation not defined\", \"Whether FBXO44-mediated BRCA1 turnover affects DNA damage responses not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that FBXO44 degrades RGS2 through a non-canonical CUL4B/DDB1 complex—not the SCF complex—revealed that FBXO44 operates in at least two distinct E3 ligase architectures with different substrate specificities.\",\n      \"evidence\": \"Genome-wide siRNA screen, reciprocal Co-IP distinguishing CUL1- and CUL4B-containing complexes, proteasomal inhibition\",\n      \"pmids\": [\"25970626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FBXO44 is partitioned between SCF and CUL4B complexes is unknown\", \"Whether additional cullins are involved was not explored\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The 2.6 Å crystal structure of Skp1–FBXO44 resolved the structural basis for loss of glycan binding: altered hydrogen-bond networks in four loops collapse the carbohydrate pocket, confirming FBXO44 engages non-glycan substrates.\",\n      \"evidence\": \"X-ray crystallography at 2.6 Å, structure-based mutagenesis\",\n      \"pmids\": [\"26460611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal with any protein substrate obtained\", \"Structure represents only the SCF-associated form, not the CUL4B complex\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapping the RGS2 N-terminal degron and showing that Ser3 phosphorylation blocks FBXO44 binding established a phosphorylation-dependent switch that protects RGS2 from degradation, paralleling classical phosphodegron logic in reverse.\",\n      \"evidence\": \"Site-directed mutagenesis, Co-IP, ubiquitination assays with RGS2 variants\",\n      \"pmids\": [\"33008920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Ser3 phosphorylation not identified\", \"In vivo relevance of phospho-protection not demonstrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that FBXO44 binds H3K9me3-marked nucleosomes at replication forks to recruit SUV39H1/CRL4/NuRD for post-replicative silencing of repetitive elements revealed a chromatin-regulatory function entirely distinct from its proteolytic roles, and linked its loss to viral mimicry and immunotherapy sensitization in cancer.\",\n      \"evidence\": \"RNAi screen, Co-IP, chromatin fractionation, loss-of-function across multiple cancer cell lines with MAVS/STING pathway readouts\",\n      \"pmids\": [\"33357448\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the chromatin function uses the CUL4B or SCF complex or neither is unclear\", \"Mechanism of H3K9me3 recognition by FBXO44 not structurally defined\", \"Whether this silencing role operates in normal (non-cancer) cells is unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of the nuclear receptor PXR as an FBXO44 substrate, with binding mediated through the F-box-associated domain to the PXR ligand-binding domain, extended the substrate repertoire to xenobiotic-sensing pathways.\",\n      \"evidence\": \"RNAi library screen, Co-IP, ubiquitination assay, domain-mapping truncations, bidirectional modulation of PXR levels\",\n      \"pmids\": [\"37969738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which cullin complex mediates PXR ubiquitination not determined\", \"Whether ligand occupancy of PXR modulates FBXO44-mediated turnover not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that AURKA phosphorylates FOXP1 at Ser440 to create a phosphodegron recognized by FBXO44, leading to K48-linked ubiquitination at K377 and derepression of Cyclin E2, established a kinase–E3 ligase axis driving colorectal cancer proliferation.\",\n      \"evidence\": \"Co-IP, K48-linkage-specific ubiquitination, phosphomimetic mutagenesis, AURKA kinase assay, in vivo xenograft\",\n      \"pmids\": [\"41051444\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other kinases can substitute for AURKA not explored\", \"Generalizability beyond colorectal cancer models not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Fine-mapping of the RGS2–FBXO44 interface by peptide arrays and AlphaFold modeling, together with identification of a small-molecule inhibitor of this interaction, provided proof-of-concept that FBXO44 substrate engagement is pharmacologically tractable.\",\n      \"evidence\": \"Systematic peptide array, AlphaFold/MD simulations, NanoBiT PPI assay, compound screening with siRNA validation\",\n      \"pmids\": [\"40992661\", \"40199141\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor potency (19.6 µM) is modest; selectivity and in vivo efficacy untested\", \"Structural model is computationally predicted and awaits experimental co-structure\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include how FBXO44 is partitioned between SCF and CUL4B complexes, the structural basis of H3K9me3 nucleosome recognition, whether the chromatin-silencing function is ubiquitin-dependent, and whether additional physiological substrates exist.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-structure of FBXO44 with any protein substrate\", \"Mechanism linking FBXO44 to H3K9me3 not structurally resolved\", \"Regulation of FBXO44 expression and turnover largely unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 3, 7, 8]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 2, 3, 7, 8]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [\n      \"SCF(FBXO44) (Skp1/CUL1/RBX1/FBXO44)\",\n      \"CUL4B/DDB1/FBXO44\"\n    ],\n    \"partners\": [\n      \"SKP1\",\n      \"CUL1\",\n      \"CUL4B\",\n      \"DDB1\",\n      \"SUV39H1\",\n      \"BRCA1\",\n      \"RGS2\",\n      \"FOXP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}